Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial

Brenda L. Bartlett, Stephen K. Tyring, Kenneth Fife, John W. Gnann, Joseph T. Hadala, Farid Kianifard, Erhan Berber

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Recurrent genital HSV outbreaks are common among those suffering from the disease. Antiviral medications taken as suppressive therapy can reduce the frequency of these recurrences and reduce viral shedding occurring in between recurrences. Objectives: To investigate the efficacy and safety of oral famciclovir as episodic (125 mg twice daily for 5 days) and suppressive (250 mg twice daily) treatment of recurrent genital herpes (RGH). Study design: This was a randomized, multicenter, 6-month, open-label study. Efficacy variables were time to first recurrence of RGH symptoms, and change in total score of the Recurrent Genital Herpes Quality of Life (RGHQoL) questionnaire. Subject satisfaction questions were summarized. Results: 384 subjects were randomized. There was a highly statistically significant difference between treatments in time to first recurrence of symptoms in favor of suppressive treatment (p < 0.0001). There was no significant difference between treatments in total score of the RGHQoL or in subject satisfaction with treatment. Conclusions: This study demonstrated that, compared to episodic treatment, suppressive treatment with oral famciclovir may extend the time to symptomatic outbreaks in patients with frequent recurrences of genital herpes.

Original languageEnglish (US)
Pages (from-to)190-195
Number of pages6
JournalJournal of Clinical Virology
Volume43
Issue number2
DOIs
StatePublished - Oct 2008

Fingerprint

Herpes Genitalis
Disease Outbreaks
Recurrence
Therapeutics
Quality of Life
Virus Shedding
famciclovir
Antiviral Agents
Safety

Keywords

  • Famciclovir
  • Genital herpes
  • Herpes simplex virus
  • Recurrent

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes : The RELIEF trial. / Bartlett, Brenda L.; Tyring, Stephen K.; Fife, Kenneth; Gnann, John W.; Hadala, Joseph T.; Kianifard, Farid; Berber, Erhan.

In: Journal of Clinical Virology, Vol. 43, No. 2, 10.2008, p. 190-195.

Research output: Contribution to journalArticle

Bartlett, Brenda L. ; Tyring, Stephen K. ; Fife, Kenneth ; Gnann, John W. ; Hadala, Joseph T. ; Kianifard, Farid ; Berber, Erhan. / Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes : The RELIEF trial. In: Journal of Clinical Virology. 2008 ; Vol. 43, No. 2. pp. 190-195.
@article{0fa74914fac84511a07e831ca43ecb4b,
title = "Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial",
abstract = "Background: Recurrent genital HSV outbreaks are common among those suffering from the disease. Antiviral medications taken as suppressive therapy can reduce the frequency of these recurrences and reduce viral shedding occurring in between recurrences. Objectives: To investigate the efficacy and safety of oral famciclovir as episodic (125 mg twice daily for 5 days) and suppressive (250 mg twice daily) treatment of recurrent genital herpes (RGH). Study design: This was a randomized, multicenter, 6-month, open-label study. Efficacy variables were time to first recurrence of RGH symptoms, and change in total score of the Recurrent Genital Herpes Quality of Life (RGHQoL) questionnaire. Subject satisfaction questions were summarized. Results: 384 subjects were randomized. There was a highly statistically significant difference between treatments in time to first recurrence of symptoms in favor of suppressive treatment (p < 0.0001). There was no significant difference between treatments in total score of the RGHQoL or in subject satisfaction with treatment. Conclusions: This study demonstrated that, compared to episodic treatment, suppressive treatment with oral famciclovir may extend the time to symptomatic outbreaks in patients with frequent recurrences of genital herpes.",
keywords = "Famciclovir, Genital herpes, Herpes simplex virus, Recurrent",
author = "Bartlett, {Brenda L.} and Tyring, {Stephen K.} and Kenneth Fife and Gnann, {John W.} and Hadala, {Joseph T.} and Farid Kianifard and Erhan Berber",
year = "2008",
month = "10",
doi = "10.1016/j.jcv.2008.06.004",
language = "English (US)",
volume = "43",
pages = "190--195",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes

T2 - The RELIEF trial

AU - Bartlett, Brenda L.

AU - Tyring, Stephen K.

AU - Fife, Kenneth

AU - Gnann, John W.

AU - Hadala, Joseph T.

AU - Kianifard, Farid

AU - Berber, Erhan

PY - 2008/10

Y1 - 2008/10

N2 - Background: Recurrent genital HSV outbreaks are common among those suffering from the disease. Antiviral medications taken as suppressive therapy can reduce the frequency of these recurrences and reduce viral shedding occurring in between recurrences. Objectives: To investigate the efficacy and safety of oral famciclovir as episodic (125 mg twice daily for 5 days) and suppressive (250 mg twice daily) treatment of recurrent genital herpes (RGH). Study design: This was a randomized, multicenter, 6-month, open-label study. Efficacy variables were time to first recurrence of RGH symptoms, and change in total score of the Recurrent Genital Herpes Quality of Life (RGHQoL) questionnaire. Subject satisfaction questions were summarized. Results: 384 subjects were randomized. There was a highly statistically significant difference between treatments in time to first recurrence of symptoms in favor of suppressive treatment (p < 0.0001). There was no significant difference between treatments in total score of the RGHQoL or in subject satisfaction with treatment. Conclusions: This study demonstrated that, compared to episodic treatment, suppressive treatment with oral famciclovir may extend the time to symptomatic outbreaks in patients with frequent recurrences of genital herpes.

AB - Background: Recurrent genital HSV outbreaks are common among those suffering from the disease. Antiviral medications taken as suppressive therapy can reduce the frequency of these recurrences and reduce viral shedding occurring in between recurrences. Objectives: To investigate the efficacy and safety of oral famciclovir as episodic (125 mg twice daily for 5 days) and suppressive (250 mg twice daily) treatment of recurrent genital herpes (RGH). Study design: This was a randomized, multicenter, 6-month, open-label study. Efficacy variables were time to first recurrence of RGH symptoms, and change in total score of the Recurrent Genital Herpes Quality of Life (RGHQoL) questionnaire. Subject satisfaction questions were summarized. Results: 384 subjects were randomized. There was a highly statistically significant difference between treatments in time to first recurrence of symptoms in favor of suppressive treatment (p < 0.0001). There was no significant difference between treatments in total score of the RGHQoL or in subject satisfaction with treatment. Conclusions: This study demonstrated that, compared to episodic treatment, suppressive treatment with oral famciclovir may extend the time to symptomatic outbreaks in patients with frequent recurrences of genital herpes.

KW - Famciclovir

KW - Genital herpes

KW - Herpes simplex virus

KW - Recurrent

UR - http://www.scopus.com/inward/record.url?scp=50849125096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50849125096&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2008.06.004

DO - 10.1016/j.jcv.2008.06.004

M3 - Article

C2 - 18621575

AN - SCOPUS:50849125096

VL - 43

SP - 190

EP - 195

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

IS - 2

ER -